Oculis (OCS) Competitors $18.74 0.00 (0.00%) As of 12:56 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. MLTX, MTSR, VKTX, KYMR, MOR, CRNX, ALVO, IMVT, CPRX, and HCMShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors MoonLake Immunotherapeutics Metsera Viking Therapeutics Kymera Therapeutics MorphoSys Crinetics Pharmaceuticals Alvotech Immunovant Catalyst Pharmaceuticals HUTCHMED MoonLake Immunotherapeutics (NASDAQ:MLTX) and Oculis (NASDAQ:OCS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings. Do institutionals and insiders hold more shares of MLTX or OCS? 93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Does the media prefer MLTX or OCS? In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Oculis. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 1 mentions for Oculis. MoonLake Immunotherapeutics' average media sentiment score of 0.89 beat Oculis' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, MLTX or OCS? MoonLake Immunotherapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, suggesting that its stock price is 71% less volatile than the S&P 500. Is MLTX or OCS more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. MoonLake Immunotherapeutics' return on equity of -30.81% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -30.81% -28.40% Oculis -13,788.70%-92.95%-70.03% Do analysts rate MLTX or OCS? MoonLake Immunotherapeutics currently has a consensus target price of $74.50, suggesting a potential upside of 58.75%. Oculis has a consensus target price of $35.33, suggesting a potential upside of 88.55%. Given Oculis' higher possible upside, analysts plainly believe Oculis is more favorable than MoonLake Immunotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation and earnings, MLTX or OCS? MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.30-20.40OculisN/AN/A-$97.43M-$2.64-7.10 SummaryMoonLake Immunotherapeutics beats Oculis on 10 of the 13 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$818.23M$2.90B$5.49B$8.93BDividend YieldN/A2.44%5.24%4.04%P/E Ratio-7.1020.9327.1520.17Price / SalesN/A191.67380.3794.17Price / CashN/A41.7026.2128.59Price / Book9.817.487.995.60Net Income-$97.43M-$55.04M$3.17B$248.41M7 Day Performance-1.16%5.32%3.51%6.03%1 Month Performance-5.92%2.44%2.80%7.70%1 Year Performance62.96%5.19%34.00%20.86% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis1.7491 of 5 stars$18.74flat$35.33+88.5%+60.7%$818.23MN/A-7.102MLTXMoonLake Immunotherapeutics1.9814 of 5 stars$47.20-0.7%$74.50+57.8%+13.0%$3.04BN/A-20.522MTSRMetseraN/A$28.45-0.5%$55.00+93.3%N/A$3.00BN/A0.0081VKTXViking Therapeutics3.8449 of 5 stars$26.50-0.1%$87.15+228.9%-46.3%$2.98BN/A-23.0420KYMRKymera Therapeutics3.3282 of 5 stars$43.64-1.1%$59.61+36.6%+44.8%$2.87B$47.07M-14.08170MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730CRNXCrinetics Pharmaceuticals3.1535 of 5 stars$28.76-4.0%$74.56+159.2%-33.7%$2.81B$1.04M-7.53210ALVOAlvotech4.006 of 5 stars$9.12-0.2%$18.00+97.4%-25.6%$2.76B$491.98M24.651,032IMVTImmunovant1.3863 of 5 stars$16.00-0.6%$38.33+139.6%-38.9%$2.75BN/A-5.84120News CoverageCPRXCatalyst Pharmaceuticals4.8994 of 5 stars$21.70-0.4%$32.83+51.3%+37.9%$2.66B$491.73M13.8280HCMHUTCHMED1.3314 of 5 stars$15.05-0.3%$19.00+26.2%-16.5%$2.63B$630.20M0.001,811 Related Companies and Tools Related Companies MLTX Competitors MTSR Competitors VKTX Competitors KYMR Competitors MOR Competitors CRNX Competitors ALVO Competitors IMVT Competitors CPRX Competitors HCM Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 7/8/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNobel Prize Material Finally Goes CommercialA Nobel Prize–winning material just got its biggest breakthrough in 30 years. A little-known company has cr...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCS Stock Alerts